CTOs on the Move

Chimerix

www.chimerix.com

 
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.chimerix.com
  • 2505 Meridian Parkway Suite 100
    Durham, NC USA 27713
  • Phone: 919.806.1074

Executives

Name Title Contact Details
Roy Ware
Chief Manufacturing and Technology Officer Profile

Funding

Chimerix raised $100M on 01/21/2021

Similar Companies

Trimeris

Trimeris is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Albany Molecular Research

Albany Molecular Research is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hitech Air Conditioning Inc

Hitech Air Conditioning Inc is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.